Biocon Revenues

The generic API business has been one of the primary businesses for Biocon, however, in recent years, the segment's contribution towards the company's consolidated financials has declined

The opportunity ahead of us is massive because over the next 10 odd years until 2032, we see 55 blockbuster molecules and biologics going out or losing exclusivity, says Tambe

Biotechnology major Biocon on Friday said its consolidated net profit rose an over two-fold to Rs 173 crore for the second quarter ended September 30, 2023. The company had reported a net profit of Rs 82 crore for the July-September period of the last fiscal. Total income rose to Rs 3,620 crore for the second quarter as against Rs 2,384 crore in the year-ago period, Biocon Ltd said in a regulatory filing. Shares of the company on Friday ended 0.11 per cent higher at Rs 227.35 apiece on the BSE.

Yesafili aims to treat various visual impairments and age-related macular degeneration

Biocon's core Ebitda came in at Rs 816 crore, up 34 per cent

Analysts estimate 38 per cent annual growth in earnings during FY20-22

Business Standard brings to you the top headlines of the day

The Bengaluru-based firm has been chasing the target since 2011